RMD ResMed
Data as of close
Healthcare · Surgical & Medical Instruments & Apparatus
ResMed (RMD) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $32.8 billion. Shares last traded at $232.90, 16.1% below their 52-week high. Over the past year the stock is down 7.8%. RMD trades at a price-to-earnings ratio of 20.56, below the Surgical & Medical Instruments & Apparatus median of 28.34. Net profit margin is 27.8%, above the peer median of -6.9%. Revenue grew 9.9% year over year. The shares yield 1.1% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.
RMD Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2026-06-30 | $350M | $2.39 | 23% |
| 2025-06-30 | $311M | $2.11 | 22% |
| 2024-06-30 | $282M | $1.91 | 28% |
| 2023-06-30 | $258M | $1.75 | 29% |
| 2022-06-30 | $245M | $1.67 | 31% |
| 2021-06-30 | $227M | $1.55 | 48% |
| 2020-06-30 | $225M | $1.55 | 36% |
| 2019-06-30 | $212M | $1.47 | 52% |
| 2018-06-30 | $199M | $1.39 | 63% |
| 2017-06-30 | $186M | $1.31 | 54% |
| 2016-06-30 | $168M | $1.19 | 48% |
| 2015-06-30 | $157M | $1.10 | 45% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2027 | $2.92 | 2026-10-30 |
| Q4 2026 (derived) | $2.64 | 2026-08-13 |
| FY 2026 | $10.43 | 2026-08-13 |
| Q3 2026 | $2.74 | 2026-05-01 |
| Q2 2026 | $2.68 | 2026-01-30 |
| Q1 2026 | $2.37 | 2025-10-31 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Surgical & Medical Instruments & Apparatus peers
RMD vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close
| SYK | Stryker Corporation | $116.8B | 32.25 | 4.44 | 13.8% | +5.32% |
| MMM | 3M | $92.2B | 26.07 | 3.65 | 14.0% | +2.35% |
| BSX | Boston Scientific | $64.3B | 18.39 | 3.05 | 16.6% | +5.62% |
| BDX | Becton Dickinson | $54.1B | 57.49 | 2.60 | 4.5% | +0.39% |
| RMD | ResMed | $32.8B | 20.56 | 5.71 | 27.8% | +1.35% |
| DXCM | DexCom | $31.6B | 31.90 | 6.19 | 19.4% | +2.99% |
| MDLN | Medline Inc. | $29.5B | — | 1.04 | — | +4.80% |
| WST | West Pharmaceutical Services | $28.4B | 44.46 | 8.36 | 18.8% | -1.15% |
| SOLV | Solventum | $14.4B | 10.06 | 1.74 | 17.3% | +4.22% |
| GKOS | Glaukos Corp | $14.1B | — | 20.48 | -24.6% | +0.53% |
| PEN | Penumbra Inc | $12.7B | 80.67 | 9.02 | 11.2% | +0.42% |
| BAX | Baxter International | $12.5B | — | 1.08 | -6.2% | +5.47% |
| GMED | Globus Medical Inc | $10.7B | 19.92 | 3.39 | 17.0% | +1.81% |
| PODD | Insulet Corporation | $10.7B | 28.39 | 3.49 | 12.3% | +2.58% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.